CENTURY THERAPEUTICS INC
IPSCNASDAQTrading Snapshot
- Day Range
- $1.43 – $1.50
- 52-Week Range
- $0.44 – $3.04
- Volume (shares)
- 839,754
- Avg Volume (shares)
- —
- Shares Outstanding
- 181.1M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $109M
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 2.3x
- EPS (TTM)
- $-0.90
- Dividend Yield
- —
- Dilution (1yr)
- +10.1%
CENTURY THERAPEUTICS INC
IPSC
StockOtter · stockotter.spaceAbout CENTURY THERAPEUTICS INC
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
PHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1
Century Therapeutics (NASDAQ:IPSC) and BioStem Technologies (OTCMKTS:BSEM) Financial Analysis
Century Therapeutics (NASDAQ: IPSC - Get Free Report) and BioStem Technologies (OTCMKTS:BSEM - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies b
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes
Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet
Century Therapeutics is rated a speculative Buy, with a $363M equity value and a focus on CNTY-813 for type 1 diabetes. IPSC's CNTY-813 aims to deliver insulin-producing islets without chronic systemic immunosuppression,
Century Therapeutics Appoints Joseph Truitt to Board of Directors
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune disease
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from o